Business Wire

GUIDEWIRE-SOFTWARE-INC

4.10.2021 11:32:11 CEST | Business Wire | Press release

Share
Guidewire Software Recognised as a Leader for Fourth Consecutive Year in the 2021 Gartner® Magic Quadrant™ for Non-Life Insurance Platforms, Europe

Guidewire Software, Inc. (NYSE: GWRE), today announced that it has been positioned as a Leader in Gartner, “Gartner Magic Quadrant for Non-Life Insurance Platforms, Europe1 ” . Guidewire was placed highest on the ability to execute axis and furthest on the completeness of vision axis. This is the fourth year that Gartner has produced a Magic Quadrant for Non-Life Insurance Platforms, Europe, and it marks the fourth year that Guidewire has been named a Leader. A complimentary copy of the report can be viewed here .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005396/en/

“Leaders have the highest combined scores for Ability to Execute and Completeness of Vision. They have a thorough market understanding, a strong non-life-insurance industry focus, and a clearly articulated vision for the future of the market and their products. Leaders offer technically solid and functionally complete software products. They have proven implementation track records with an adequate installed base,” according to the Gartner report.

“We are honoured to be recognised by Gartner for the fourth year in a row as a Leader in its Magic Quadrant for Non-Life Insurance Platforms, Europe,” said Laurent Fontaine, group vice president, Sales, EMEA, Guidewire Software. “We are committed to leading technology innovation in the non-life insurance industry and are setting the bar with our cloud-optimised platform. Customer success remains our top priority and we embrace those insurers seeking to modernise their legacy infrastructures and those wanting to test cloud by quickly bringing new business to market via a greenfield approach.”

Guidewire’s momentum with InsuranceSuite during 2020 – 2021 includes:

  • Twice yearly releases of the Guidewire platform (Aspen and Banff in 2020, and Cortina so far in 2021), delivered as a cloud service, to accelerate innovation. Complex upgrades are a thing of the past, and operation and maintenance burdens are transferred to Guidewire.
  • Delivery of Guidewire Cloud Platform which provides a Guidewire-engineered architecture for the cloud. It includes infrastructure, application services, and data services and enables the provisioning, scalability, and security of Guidewire cloud products.
  • The reimagined Guidewire core platform with embedded analytics and native support for digital experiences for customers, agents, and employees — the most complete P&C insurance platform in the world.
  • The industry’s first smart-loop analytics platform which enables improved understanding of risk signal, more automated processes, better decision-making, a better customer experience, and improved business intelligence.
  • A complete set of APIs and integration tools, along with a world-class developer experience, that accelerate innovation while making it easier to integrate with other systems and build add-ons through a growing Guidewire Marketplace .
  • Product functional completeness, tooling, and methodology to continually drive down the cost of implementing and operating the Guidewire platform.

*Additional Recognition:

  • Magic Quadrant for P&C Core Platforms, North America, named a Leader seven consecutive times*

1 Gartner, Magic Quadrant for Non-Life Insurance Platforms, Europe, James Ingham , Sham Gill , 27 September 2021
Gartner, Magic Quadrant for P&C Core Platforms, North America, James Ingham , Sham Gill ,14 September 2021
Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Disclaimer

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About Guidewire

Guidewire is the platform general insurers trust to engage, innovate, and grow efficiently. We combine digital, core, analytics, and AI to deliver our platform as a cloud service. More than 400 insurers, from new ventures to the largest and most complex in the world, run on Guidewire.

As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.

For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye